Navidea Biopharmaceuticals to Present at the 7th Annual LD Micro Invitational Investor Conference
June 01 2017 - 4:50PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) (“Navidea” or
“the Company”), a company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics, today announced it will present at the 7th
Annual LD Micro Invitational investor conference being held June
6-7, 2017 in Los Angeles, CA. Michael Goldberg, M.D., Chief
Executive Officer of Navidea, will be giving a presentation and
meeting with investors throughout the conference.
Event: 7th Annual LD Micro
InvitationalPresentation Date: June 6, 2017Presentation
Time: 3:00 PM PTLocation: Luxe Sunset Boulevard Hotel,
Los Angeles, CA
Dr. Goldberg said, “I am proud to give an introduction to, and
in some cases an update of, Navidea to high-quality investors.
We’ve recently achieved significant milestones and have a pipeline
of clinical development announcements upcoming. Navidea is at an
exciting point, and we are eager to share our plans with the
investment community.”
“This year, not only do we have a record number of companies
making their LD Micro debuts, but a record number of companies
presenting for the first time in their company’s history,” stated
Chris Lahiji, President of LD Micro. “LD has established itself as
the one venue that brings the most influential players from all
segments of the market under one roof.”
For investors attending the LD Micro Invitational conference,
please contact Navidea Investor Relations to schedule a meeting
with Navidea management at tpatel@edisongroup.com or
ir@navidea.com.
The presentation will be webcast live and remain available for
90 days following the presentation. To access the webcast, please
visit the Events tab of the Investor Relations section of the
Navidea website at www.navidea.com.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products based on its ManoceptTM platform to
enhance patient care by identifying the sites and pathways of
disease and enable better diagnostic accuracy, clinical
decision-making, and targeted treatment. Navidea’s Manocept
platform is predicated on the ability to specifically target the
CD206 mannose receptor expressed on activated macrophages. The
Manocept platform serves as the molecular backbone of Tc 99m
tilmanocept, the first product developed and commercialized by
Navidea based on the platform. The development activities of the
Manocept immunotherapeutic platform are being conducted by Navidea
in conjunction with its subsidiary, Macrophage Therapeutics, Inc.
Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel products and advancing the
Company’s pipeline through global partnering and commercialization
efforts. For more information, please visit www.navidea.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into an
event platform hosting several influential conferences annually
(Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to exclusively provide intraday information on the entire sector.
LD will continue to provide valuable tools for the benefit of
everyone in the small and microcap universe.
For those interested in attending, please contact David Scher at
david@ldmicro.com or visit www.ldmicro.com for more
information.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170601006640/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin,
614-551-3416CFO/COOjlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035Investors (Global)tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024